CD274 and esophageal squamous cell carcinoma: Serplulimab combined with chemotherapy is a novel therapeutic approach for patients with aESCC and PD-L1 positivity, according to the results of the prospective phase 3 ASTRUM-007 randomized clinical trial, challenging the traditional classification and treatment paradigm of ESCC.